New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How would you treat SLE (inflammatory arthritis, +ANA/dsDNA/SSA) overlap with RA (CCP high titer) in a young female of childbearing age with low TPMT?

2 Answers

Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Whenever I have a patient with more than one systemic autoimmune disease, I often wonder which genotype/endotype is driving which manifestation. In this case... is it truly RA-driven inflammatory arthritis, or is it SLE arthritis? Depending on the cohort, around 25% of SLE patients are anti-CCP posi...

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · Mayo Clinic College of Medicine

Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...

In a young patient who was vaccinated against chickenpox as a child (no previous varicella infection), should the patient receive a shingles vaccine prior to starting Rinvoq?

2
5 Answers

Mednet MemberInvited Expert
Gastroenterology · Northwestern Medicine

Yes. The vaccines are different and current vaccine is to prevent zoster for patients who have been previously exposed to varicella or vaccinated for varicella.

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What strategies have you found most effective in improving long-term medication adherence in patients with SLE?

2
2 Answers

Mednet MemberInvited Expert
Rheumatology · Penn Medicine

Patient education and buy-in are key for achieving long-term medication adherence. Medication adherence is the outcome of several factors, including but not limited to access to healthcare: appointments, laboratory visits, transportation, health literacy, medication fatigue, and response to therapy,...

In patients treated with infliximab, do rates of immunogenicity vary based on underlying disease (RA, IBD, sarcoidosis, etc) and/or baseline disease activity?

2
1 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Yes, rates of infliximab immunogenicity appear to vary based on underlying disease, with evidence showing higher rates for RA than IBD and spondyloarthritis, and tend to increase with higher baseline disease activity. Most patients tend to develop anti-drug antibodies within the first year, but this...

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Typically if a patient has required treatment with steroids for four to six months, it was because their irAE was significant (grade 2-4) and refractory to initial treatment. If the patient received combination immunotherapy, such as anti-CTLA-4 and anti-PD-1 agents, one could consider resuming the ...

How often do you draw screening ANAs for discoid lupus?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...

How do you approach a patient with GCA who has an allergic reaction to a biosimilar of tocilizumab but did well previously on originator tocilizumab?

1
1 Answers

Mednet Member
Rheumatology · Virginia Mason Franciscan Health Rheumatology Fellowship

I wonder whether they may have had a reaction to one of the inactive ingredients in the biosimilar! I would try to switch back to the originator tocilizumab. If unsuccessful, even with an appeal, I could also consider trying the other biosimilar available in the market, although, I would prefer to u...

How do you manage a possible autoimmune sialadenitis arising from checkpoint inhibitor therapy?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Ohio State University

This is a great question and a common clinical scenario in patients receiving immune checkpoint inhibitors. In my experience, severe sicca symptoms from immunotherapy are often not classic primary Sjögren's syndrome, despite some overlapping features. Rather, this appears to be an acute T-cell-media...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...